Breast Cancer

Key opinion leaders share insight on various mechanisms of resistance to frontline therapy in patients with HR+/HER2- metastatic breast cancer.

A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.

Heather Han, MD, discusses breakthrough data from the phase 3 DESTINY-Breast04 trial.

Amit Jain, MD, discusses the potential role of emerging biomarkers in selecting treatment with CDK7 inhibitors in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Francois-Clement Bidard, MD, PhD, discusses the importance of elacestrant in estrogen receptor–positive, HER2-negative, advanced or metastatic breast cancer.

The FDA has removed the clinical hold on the phase 3 FLAMINGO-01 trial allowing the study to continue elevating the activity and safety of the HER2/neu-peptide GLSI-100 in patients with HER2/neu-positive breast cancer who are at high risk for disease recurrence or have residual disease following completion of neoadjuvant and adjuvant trastuzumab-based therapy, according to an announcement from the drug developer.

The FDA has accepted for review a biologics license application for vic-trastuzumab duocarmazine for the treatment of patients with HER2-positive unresectable locally advanced or metastatic breast cancer.

Vered Stearns, MD, FASCO, discusses how DESTINY-Breast04 has shifted the treatment paradigm for patients with HER2-low breast cancer, the exploration of treatment combinations being optimized in breast cancer, and the expansion of the treatment paradigm in triple-negative breast cancer.

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v

Subject matter experts in breast oncology discuss ongoing clinical trials in early-stage HER2+ breast cancer that focus on perioperative therapies.

Expert oncologists share their perspectives on when it would be appropriate to consider neratinib therapy in early-stage HER2+ breast cancer.

Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.

Dr Tarantino discusses practice-changing findings in breast cancer and emphasizes the ways in which positive study data can improve the breast cancer treatment paradigm going forward.

Praluzatamab ravtansine achieved a promising overall response rate in patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Real-world evidence is finding an expanded role in oncology, prompting experts to rethink how data are gathered on the day-to-day usefulness of drugs for regulatory decisions.

Gregory Vidal, MD, PhD, including the evolution of treatment options for HER2-low breast cancer, emerging antibody-drug conjugates in triple-negative disease, and the viability of HER3 as an emerging target in breast cancer

A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.

Richard Finn, MD, considers data behind all three approved CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer and how they compare.

Taking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.

A brief discussion on the role of trastuzumab emtansine, T-DM1, in patients with early-stage HER2+ breast cancer.

Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.

Panelists review clinical data behind subcutaneous HP therapy in early stage HER2+ breast cancer and elucidate the real-world use of this approach.

Drug manufacturer Aileron plans to stop further enrollment into a phase 1b trial (NCT04022876) after the chemoprotective agent ALRN-6924 missed its composite primary end point for patients with advanced p53-mutant non–small cell lung cancer.

Adding atezolizumab to neoadjuvant standard of care therapy for HER2-positive early breast cancer did not result in a better pathologic complete response compared with placebo, according to findings from the phase 3 IMpassion050 trial.

Expert perspectives on the pooled analysis from MONARCH 2 and MONARCH 3, combining frontline abemaciclib with fulvestrant.